Literature DB >> 10843958

Bronchial inflammation: its relationship to colonizing microbial load and alpha(1)-antitrypsin deficiency.

R A Stockley1, A T Hill, S L Hill, E J Campbell.   

Abstract

Neutrophil elastase is capable of generating many of the features of chronic bronchial disease. In patients with COPD, airways inflammation with neutrophil recruitment and elastase release is positively correlated with colonizing bacterial load in the stable clinical state (p < 0.0005). In addition, alpha(1)-antitrypsin deficiency is associated with a greater neutrophil load, higher elastase activity, leukotriene-B(4) concentration, and serum protein leak than matched patients without deficiency (p < 0.005). These data confirm an effect of bronchial colonization on airways inflammation in COPD and indicate the role of alpha(1)-antitrypsin in its modulation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10843958     DOI: 10.1378/chest.117.5_suppl_1.291s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  8 in total

1.  Rationale and Design of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis Study. Alpha-1 Protocol.

Authors:  Charlie Strange; Robert M Senior; Frank Sciurba; Scott O'Neal; Alison Morris; Stephen R Wisniewski; Russell Bowler; Harry S Hochheiser; Michael J Becich; Yingze Zhang; Joseph K Leader; Barbara A Methé; Naftali Kaminski; Robert A Sandhaus
Journal:  Ann Am Thorac Soc       Date:  2015-10

2.  Neutrophilic inflammation and IL-8 levels in induced sputum of alpha-1-antitrypsin PiMZ subjects.

Authors:  M Malerba; F Ricciardolo; A Radaeli; C Torregiani; L Ceriani; E Mori; M Bontempelli; C Tantucci; V Grassi
Journal:  Thorax       Date:  2005-11-11       Impact factor: 9.139

Review 3.  Pneumocystis: a novel pathogen in chronic obstructive pulmonary disease?

Authors:  Alison Morris; Frank C Sciurba; Karen A Norris
Journal:  COPD       Date:  2008-02       Impact factor: 2.409

4.  Prolastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine release.

Authors:  Izabela Nita; Camilla Hollander; Ulla Westin; Sabina-Marija Janciauskiene
Journal:  Respir Res       Date:  2005-01-31

5.  The Biological Effects of Double-Dose Alpha-1 Antitrypsin Augmentation Therapy. A Pilot Clinical Trial.

Authors:  Michael A Campos; Patrick Geraghty; Gregory Holt; Eliana Mendes; Paul R Newby; Shuren Ma; Landy V Luna-Diaz; Gerard M Turino; Robert A Stockley
Journal:  Am J Respir Crit Care Med       Date:  2019-08-01       Impact factor: 21.405

Review 6.  Lung microbiology and exacerbations in COPD.

Authors:  Victoria Beasley; Priya V Joshi; Aran Singanayagam; Philip L Molyneaux; Sebastian L Johnston; Patrick Mallia
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-08-31

7.  Soluble triggering receptor expressed on myeloid cells 1 is released in patients with stable chronic obstructive pulmonary disease.

Authors:  Markus P Radsak; Christian Taube; Philipp Haselmayer; Stefan Tenzer; Helmut R Salih; Rainer Wiewrodt; Roland Buhl; Hansjörg Schild
Journal:  Clin Dev Immunol       Date:  2007

8.  Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial.

Authors:  Roshan Siva; Mona Bafadhel; William Monteiro; Christopher E Brightling; Ian D Pavord
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-02-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.